| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 10.34M | 135.16M | 91.37M | 53.91M | 200.58M | 853.00K | 
| Gross Profit | 9.43M | 135.16M | -129.20M | 47.16M | 118.29M | -74.03M | 
| EBITDA | -248.10M | -154.56M | -190.11M | -131.56M | 71.97M | -111.22M | 
| Net Income | -302.92M | -122.31M | -147.03M | -116.95M | 66.97M | -111.14M | 
| Balance Sheet | ||||||
| Total Assets | 399.07M | 547.11M | 696.38M | 758.03M | 609.37M | 332.98M | 
| Cash, Cash Equivalents and Short-Term Investments | 371.44M | 471.39M | 618.83M | 710.41M | 579.09M | 295.38M | 
| Total Debt | 9.78M | 10.84M | 11.84M | 6.47M | 12.33M | 17.84M | 
| Total Liabilities | 74.73M | 60.18M | 135.02M | 135.99M | 143.32M | 148.97M | 
| Stockholders Equity | 324.33M | 486.93M | 561.37M | 622.04M | 466.04M | 184.01M | 
| Cash Flow | ||||||
| Free Cash Flow | -196.69M | -150.35M | -136.72M | -109.28M | 92.03M | -80.56M | 
| Operating Cash Flow | -196.74M | -150.05M | -133.91M | -108.82M | 92.61M | -80.36M | 
| Investing Cash Flow | -184.94K | -298.00K | -2.77M | -464.00K | -575.00K | -196.00K | 
| Financing Cash Flow | 147.29K | 1.55M | 45.10M | 241.46M | 190.33M | 215.00K | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | $483.32M | -3.99 | -65.30% | ― | 1504.83% | 56.81% | |
| ― | $568.09M | -186.03 | 3.53% | ― | 158.57% | 96.76% | |
| ― | $573.29M | -1.89 | -66.85% | ― | -95.24% | -493.05% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $420.53M | -22.55 | -12.42% | ― | 194.98% | 38.01% | |
| ― | $490.14M | ― | -66.35% | ― | ― | -25.20% | |
| ― | $572.27M | ― | -68.67% | ― | ― | -50.83% | 
On August 27, 2025, Prothena announced results from its Phase 1 ASCENT clinical program for the investigational drug PRX012, aimed at treating early symptomatic Alzheimer’s disease. The study demonstrated that PRX012, a once-monthly, subcutaneous anti-amyloid beta antibody, showed promising results in reducing amyloid plaque but had higher ARIA-E rates compared to FDA-approved antibodies. Prothena plans to seek partnerships to further develop PRX012 and its preclinical PRX012-TfR antibody, which may offer a reduced risk of ARIA and quicker amyloid plaque reduction.
The most recent analyst rating on (PRTA) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
On August 6, 2025, Prothena announced that its partner Novo Nordisk will advance coramitug, a potential first-in-class amyloid depleter antibody, into Phase 3 development for ATTR amyloidosis with cardiomyopathy. This decision follows the successful completion of a Phase 2 trial and is expected to commence in 2025. Prothena stands to earn a clinical milestone payment upon meeting specific enrollment criteria in the Phase 3 trial. The advancement of coramitug marks a significant step in addressing the unmet needs of patients with ATTR amyloidosis, potentially enhancing Prothena’s industry positioning and offering substantial financial benefits through its agreement with Novo Nordisk.
The most recent analyst rating on (PRTA) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
Prothena Corporation plc is a biotechnology company specializing in the development of therapeutics for neurodegenerative and rare peripheral amyloid diseases, leveraging its expertise in protein dysregulation. In its latest earnings report, Prothena highlighted significant advancements in its pipeline, including the progression of prasinezumab into Phase 3 trials for Parkinson’s disease and the upcoming release of initial data from the Phase 1 ASCENT clinical trials for Alzheimer’s treatment PRX012. Financially, Prothena reported a net loss of $125.8 million for the second quarter of 2025, attributed to restructuring charges and a non-cash income tax expense, with total revenue significantly lower than the previous year due to reduced collaboration revenue. The company maintains a strong cash position of $372.3 million, with expectations to end the year with approximately $298 million. Looking ahead, Prothena plans to convene an Extraordinary General Meeting by year-end to propose a share capital reduction, potentially enabling a share redemption program, while continuing to advance its clinical programs and collaborations.
On July 30, 2025, Prothena Biosciences Inc entered into employment agreements with key executives, including the Chief Strategy Officer, Chief Operating Officer, and Chief Scientific Officer. These agreements outline their base salaries, bonus opportunities, and severance benefits, which align with the company’s existing severance plan. The agreements provide for enhanced severance benefits in the event of termination without cause or resignation for good reason, with further increases if such termination occurs in connection with a change in control. This move is likely to impact the company’s operations by securing leadership stability and potentially positioning the company more favorably in the industry.
The most recent analyst rating on (PRTA) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.